
































































Cancer	 cachexia	 is	 a	 devastating	 metabolic	 syndrome	 characterized	 by	
systemic	inflammation	and	massive	muscle	and	adipose	tissue	wasting.	Although	
cancer	 cachexia	 is	 responsible	 for	 about	 25%	 of	 cancer	 deaths,	 no	 effective	
therapies	 are	 available,	 and	 the	 underlying	 mechanisms	 have	 not	 been	 fully	
elucidated.	
Its	 occurrence	 complicates	 patients’	management,	 reduces	 tolerance	 to	
treatments	and	negatively	affects	patient	quality	of	life.	Muscle	wasting,	mainly	
due	to	increased	protein	breakdown	rates,	is	one	of	the	most	prominent	features	
of	 cachexia.	 Blocking	 muscle	 loss	 in	 cachexia	 mouse	 models	 dramatically	
prolongs	survival	even	of	animals	in	which	tumor	growth	is	not	inhibited.		
Recent	 observations	 showed	 that	 bone	 morphogenetic	 protein	 (BMP)	
signaling,	 acting	 through	 Smad1,	 Smad5	 and	 Smad8	 (Smad1/5/8),	 is	 a	 master	






checked	 the	 state	 of	 activation	 of	 the	 BMP	 pathway	 in	 muscle	 of	 cachectic	 vs	
non–cachectic	patients	affected	by	colon,	pancreatic	and	esophagus	cancer	and	in	
control	 subjects.	 We	 checked	 by	 Western	 Blot	 the	 phosphorylation	 levels	 of	
Smad1/5/8	 and	 of	 Smad3	 and	 by	 quantitative	 Real-Time	 PCR	 (qRT-PCR)	 the	
expression	 levels	 of	 different	 atrophy-related	 genes	 The	 second	 aim	 was	 to	
evaluate	 the	 degree	 of	 muscle	 atrophy	 and	 distribution	 of	 muscle	 fibers	 in	








of	 cancer	 patients	 and	 11	 from	 control	 subjects.	 In	 line	 with	 the	 results	 we	
obtained	 in	 C26	 mice	 model	 (a	 well-established	 cancer	 cachexia	 experimental	
model)	 Smad1/5/8	 phosphorylation,	 readout	 of	 the	 state	 of	 activation	 of	 the	
BMP	 pathway,	 was	 nearly	 completely	 abrogated	 in	 the	 muscles	 of	 cancer	
cachectic	 patients	 compared	 to	 cancer	 non-cachectic	 ones.	 Interestingly,	 the	
level	 of	 phosphorylation	 of	 Smad3	 was	 not	 significantly	 affected	 suggesting	
specific	 effects	 of	 cancer	 growth	 on	 BMP	 pathway.	 The	 expression	 levels	 of	
different	atrophy-related	genes	 including	MUSA1	were	induced	in	the	cachectic	
muscles.	 Interestingly,	 several	 BMP	 related	 genes	 are	 also	 changing	 the	
expression	 during	 cancer	 growth.	 We	 also	 found	 a	 correlation	 between	
suppression	of	BMP		pathway,	expression	of	atrophy	related	genes	and	Noggin,	
known	to	block	BMP	pathway.		
	 Morphometric	 analysis	 shown	 that	 patients	 with	 cancer	 cachexia	 have	
smaller	myofiber	diameter	 (in	particular	 fast	 type	 fibers)	 in	comparison	 to	age-
matched	 controls.	 In	 skeletal	muscle	 from	 cancer	 patients	 (either	 cachectic	 or	
non-cachectic)	we	detected	a	prevalence	of	flat	shaped,	angulated	and	severely	
atrophic	 myofibers	 (i.e.	 morphological	 features	 of	 denervated	 myofibers),	 big	
fiber-type	 grouping	 (i.e.	 typical	 hallmark	 of	 denervation/reinnervation	 events)	
and	numerous	NCAM	positive	myofibers	(i.e.	specific	marker	of	denervation).	
CONCLUSIONS	
	 These	 findings	are	consistent	with	 the	hypothesis	 that	BMP	 inhibition	 is	
permissive	 to	 cachexia	 onset.	 Since	 the	 reactivation	 of	 the	 BMP-dependent	
signaling	 and	 MUSA1	 suppression	 was	 sufficient	 to	 prevent	 tumor-induced	















The	 aim	 of	 this	 study	 is	 to	 investigate	 the	 role	 of	 the	 BMP	 axis	 and	 its	
target	 gene	 MUSA1	 in	 cancer	 cachexia	 in	 human	 cancer	 patients	 in	 order	 to	




-	 to	 assess	 the	 state	 of	 activation	 of	 the	 BMP	 pathway	 (level	 of	
phosphorylation	 of	 Smad1/5/8)	 and	 TGFb/myostatin	 pathway	 (level	 of	
phosphorylation	 of	 Smad3)	 in	 muscle	 biopsies	 from	 control	 patients,	 non-
cachectic	and	cachectic	cancer	patients;	
-	 to	 evaluate	 the	 expression	 of	 BMP	 dependent	 E3-ubiquitin	 ligase	
MUSA1	 in	 muscle	 biopsies	 from	 control	 patients,	 non-cachectic	 and	 cachectic	




















caused	 by	 a	 combination	 of	 reduced	 food	 intake	 and	 abnormal	 metabolism,	
seemingly	induced	by	tumor-	and	host-derived	factors.	It	is	not	known	precisely	
how	or	why	cancer	so	frequently	develops	in	such	a	way	as	to	induce	cachexia.		
Cachexia	 has	 commonly	 been	 considered	 a	 paraneoplastic	 syndrome	 in	
which	tumor-derived	factors	induce	widespread	alterations	in	gene	expression	or	
metabolic	flux	that	may	function	to	release	intermediate	metabolites,	which	can	
then	be	used	by	 the	 tumor	 for	growth	and	expansion1.	 In	 this	model,	 cachexia	
can	be	considered	a	state	of	 ‘‘autocannibalism’’	 in	which	the	tumor	survives	at	
the	expense	of	the	host.	In	contrast,	many	of	the	metabolic	changes	in	cachexia	
are	 the	 result	 of	 activated	 immune	 and	 neuroendocrine	 responses	 that	 are	






















depends	 on	 factors	 such	 as	 cancer	 type	 and	 stage,	 the	 presence	 of	 systemic	
inflammation,	 low	 food	 intake	 and	 lack	 of	 response	 to	 anticancer	 therapy.	
Patients	 who	 have	 more	 than	 5%	 loss	 of	 stable	 body	 weight	 over	 the	 past	 6	
months,	or	a	body-	mass	index	(BMI)	less	than	20	kg/m2	and	ongoing	weight	loss	
of	more	than	2%,	or	sarcopenia	and	ongoing	weight	 loss	of	more	than	2%,	but	
have	 not	 entered	 the	 refractory	 stage,	 are	 classified	 as	 having	 cachexia.	 In	




advanced	 cancer	 (preterminal)	 or	 the	 presence	 of	 rapidly	 progressive	 cancer	




months.	 The	 burden	 and	 risks	 of	 artificial	 nutritional	 support	 are	 likely	 to	
outweigh	 any	 potential	 benefit.	 Therapeutic	 interventions	 focus	 typically	 on	
alleviating	the	consequences	and	complications	of	cachexia	as	symptom	control	
(appetite	 stimulation,	 management	 of	 nausea	 or	 eating-related	 distress	 of	
patients	and	families).	




implications	 than	 the	 same	 loss	 from	 an	 initial	 value	 of	 35.	 Furthermore,	 a	
patient	with	 a	BMI	of	 30	 and	a	history	of	weight	 loss	 is	more	 at	 risk	 if	muscle	





Cancer	 cachexia	 can	 vary	 according	 to	 tumor	 type,	 site,	 and	mass4.	 The	
anatomical	 position	 of	 a	 tumor	 in	 the	 upper	 gastrointestinal	 tract	may	 lead	 to	
obstruction	and	reduce	food	 intake	directly.	The	relationship	between	cachexia	
and	tumor	mass	is	complex.	In	many	animal	models	the	tumor	grows	quickly	and	
reaches	>10%	of	body	mass	acting	as	a	 ‘‘nitrogen	 trap’’5.	 In	humans,	however,	
tumor	burden	is	often	<1%	when	there	is	profound	cachexia,	suggesting	that	the	




high	 tumor	 IL-6	 production	 has	 been	 associated	with	 cachexia6,	 and	 increased	
levels	 of	 tumor-derived,	 or	 tumor-	 induced	 but	 host-derived,	 proinflammatory	




Genetic	 variation	 in	 immunity	 and	 associated	 signaling	 pathways	 is	 known	 to	
relate	to	outcomes	in	major	sepsis7,	and	recent	findings	suggest	a	similar	pattern	
in	 cancer	 cachexia.	 Single-nucleotide	polymorphisms	 in	 the	 IL-1,	 IL-6,	 and	 IL-10	
genes	 that	 are	 linked	 to	 production	 rates	 of	 these	 cytokines	 have	 been	
associated	with	 the	prevalence	of	cachexia	 in	gastric	or	pancreatic	cancer8.	For	
example,	 the	 1082G	 allele	 in	 the	 IL-10	 promoter	 has	 been	 validated	 as	 a	
procachectic	 genotype	 in	 an	 independent	 cohort9.	 IL-10	has	been	 shown	 to	be	
elevated	in	a	Myc/mTOR-driven	murine	model	of	cancer	cachexia	(Robert	et	al.,	





the	 variable	 presentation	 of	 cachexia.	 However,	 currently	 no	 genome-	 wide	
studies	in	either	animal	models	or	patients	have	been	performed.		
The	classical	presentation	of	cachexia	is	of	an	extremely	thin	and	wasted	
individual.	However,	heterogeneity	 in	 this	clinical	presentation	 is	 introduced	by	
the	 current	 epidemic	 of	 obesity.	 When	 healthy	 individuals	 develop	 a	 chronic	
disease,	the	higher	risk	associated	with	obesity	is	reversed	and	obesity	becomes	
‘‘protective,’’	perhaps	due	to	increased	adipose	and	lean	tissue	reserves.	This	is	
known	 as	 the	 obesity	 paradox.	Mean	 BMI	 of	 advanced	 cancer	 patients	 is	 now	
commonly	measured	at	>25.	There	is,	however,	a	subgroup	of	these	overweight	
patients	 who	 hide	 gross	 muscle	 wasting	 under	 a	 mantle	 of	 adipose	 tissue.	







than	 women	 and	 one	 might	 assume	 that	 this	 greater	 ‘‘reserve’’	 would	 be	





1.2	 MUSCLE	 ATROPHY	 IN	 CANCER	
CACHEXIA	
 
Loss	 of	 skeletal	 muscle	 mass	 in	 cancer	 cachexia	 is	 generally	 due	 to	
reduced	protein	synthesis,	increased	degradation,	or	a	relative	imbalance	of	the	









Figura	 1	 Atrophy	 and	 hypertrophy	 pathways	 in	 skeletal	






into	 two	 established	 pathways,	 the	 NF-kB	 pathway	 (weakly	 in	 the	 case	 of	
TWEAK)	 and	 p38	 MAP	 kinase.	 These	 two	 signaling	 mediators	 are	 required	 to	
upregulate	 the	expression	of	 the	key	E3	 ligases	 (muscle	RING	 finger-containing	
protein	1,	MURF1,	and	muscle	atrophy	F	box	protein,	MAFbx,	otherwise	known	
as	 Atrogin-1),	 which	 mediate	 sarcomeric	 breakdown	 and	 inhibition	 of	 protein	
synthesis14.	MuRF1	 is	upregulated	 in	multiple	settings	of	muscle	atrophy15.	This	




tumor-induced	 muscle	 loss,	 at	 least	 in	 mice,	 in	 part,	 by	 inhibiting	 the	
upregulation	of	MuRF119.		
The	RING	finger	 in	MuRF1	binds	zinc,	which	 is	required	for	 its	activity,	as	 is	the	
case	with	all	RING	 finger-containing	E3s20.	One	 recent	 study	demonstrates	 that	
zinc	 accumulates	 during	 cachexia,	 speculating	 that	 this	 may	 help	 induce	
ubiquitination	by	zinc-dependent	E3s21.	MAFbx/Atrogin-1	also	 serves	as	a	high-
fidelity	marker	of	acute	muscle	atrophy,	being	upregulated	in	multiple	settings	of	
cachexia22,	 in	 addition	 to	 immobilization,	 denervation,	 and	 glucocorticoid	
excess23.	MAFbx	up-	regulation	occurs	via	p38	activation	(Li	et	al.,	2005)	and	by	
the	induction	of	the	C/EBPb	transcription	factor,	which	itself	is	activated	through	
p38	 phosphorylation24.	MAFbx	 induces	 the	 ubiquitination	 of	 an	 eIF3f,	which	 is	
part	 of	 the	 protein	 translation	 machinery25.	 However,	 it	 is	 not	 clear	 if	 this	 is	
sufficient	to	decrease	protein	synthesis.	Some	studies	in	cachectic	tumor-bearing	











The	 E3	 ligase	 Fbxo40	may	be	 able	 to	 contribute	 to	 atrophy	by	 inducing	
the	 ubiquitination	 of	 IRS1	 and	 thereby	 short-circuiting	 the	 IGF1/IGF1R/IRS1	
pathways	and	downstream	protein	synthesis	activation27.	Fbxo40	is	able	to	cause	
IRS1	 to	 be	 degraded	 upon	 its	 phosphorylation	 by	 the	 IGF1R.	 Under	 settings	
where	 protein	 synthesis	 is	 ongoing,	 this	 would	 not	 be	 expected	 to	 decrease	
signaling	 in	a	sustained	fashion,	because	the	degraded	IRS1	could	simply	be	re-
synthesized,	 and	 signaling	 could	 thereby	 continue.	 However,	 under	 conditions	
where	 protein	 synthesis	 is	 blocked,	 IRS1	 would	 not	 be	 replenished,	 and	 IGF1	
signaling	would	 thereby	be	silenced.	Some	 indication	 that	 this	might	happen	 is	
supported	 by	 a	 recent	 study	 suggesting	 that	 Fbxo40	 is	 upregulated	 upon	
denervation.	It	remains	to	be	determined	whether	this	happens	in	other	settings	
of	 muscle	 atrophy28.	 Hypertrophy	 Signaling	 and	 Links	 with	 Atrophy	 Pathways	
Opposing	 skeletal	 muscle	 atrophy	 are	 those	 pathways	 that	 induce	 muscle	
hypertrophy.	 One	 of	 the	 best-characterized	 mechanisms	 for	 inducing	
hypertrophy	 is	 through	 IGF1	 (insulin-	 like	 growth	 factor	 1)	 signaling.	 IGF1	 is	
upregulated	 in	skeletal	muscle	normally	during	resistance	exercise29,	helping	to	
explain	why	there	is	asymmetric	hypertrophy	of	particular	muscles	depending	on	
work	 and	 resistance.	 The	 pathway	 that	 mediates	 hypertrophy	 downstream	 of	
IGF1	 activation	 is	 IRS1/PI3K/Ak30.	 Under	 atrophy	 conditions,	 autophagy	 is	
induced	 in	addition	 to	ubiquitin-mediated	proteolysis.	However	while	blockade	
of	ubiquitin	 signaling,	 for	example	using	 the	proteasome	 inhibitor	Velcade,	has	
been	 demonstrated	 to	 result	 in	 healthy	 preserved	 muscle31,	 developmental	
blockade	 of	 autophagy	 results	 in	 pathologic	muscle32.	 In	 addition	 to	 activating	
TORC1	 signaling,	 Akt	 also	 phosphorylates	 the	 Foxo	 (or	 Forkhead)	 family	 of	
transcription	factors.	Foxo1	and	Foxo3	play	a	key	role	in	inducing	transcriptional	
upregulation	of	MuRF1	and	MAFbx33.	Apparently	these	transcription	factors	are	




of	 the	 E3	 ligases.	 In	 addition,	 transgenic	 overexpression	 of	 Foxo3	 in	 skeletal	




The	mass	of	protein	within	a	muscle	 is	 regulated	by	 the	net	 interplay	between	
protein	synthesis	and	degradation.	In	rodent	models	of	cancer-associated	muscle	
wasting,	 both	 decreased	 synthesis	 and	 increased	 degradation	 have	 been	
described36.	 There	 have	 only	 been	 a	 few	 direct	 measurements	 of	 protein	
synthesis	 in	humans	with	cancer	cachexia.	Protein	synthesis	has	been	shown	to	
be	 decreased37	 with	 only	 indirect	 evidence	 available	 on	 the	 issue	 of	 protein	
degradation.		
Transcriptional	 activation	 of	 ubiquitin	 proteasome	 pathway	 (UPP)	
components	has	been	found	in	the	skeletal	muscle	of	both	rodent	models38	and	







Using	 genome-wide	 transcript	 analysis	 of	 sequential	 quadriceps	muscle	
biopsies	 in	patients	before	and	after	curative	surgery	 for	upper	gastrointestinal	
cancer,	 a	 recent	 study	 has	 shown	 that	 1,868	 genes	 were	 regulated	 in	 the	
cachectic	 state.	 Ontology	 analysis	 demonstrated	 that	 these	 gene	 products	 be-	
longed	 to	 both	 anabolic	 and	 catabolic	 biological	 processes,	 which	 were	





predominant	 decrease	 in	 synthesis	 in	 the	 early	 phase	 of	 cancer	 cachexia.	
Interestingly,	 it	 has	 been	 suggested	 that	MAFbx	 expression	 is	 a	 poor	 index	 of	
muscle	 proteolysis	 and	 may	 instead	 be	 predominantly	 linked	 with	 controlling	
protein	synthesis43.		
In	addition	to	regulating	UPP,	Foxo	transcription	factors	directly	regulate	genes	
coding	 for	 the	 autophagy	 pathway,	 which	 like	 the	 ubiquitin	 system	 also	
contributes	 to	 the	 degradation	 of	 muscle	 proteins	 to	 promote	 atrophy.	 In	
autophagy,	 organelles	 are	 sequestered	 in	 autophagosome	 vacuoles	 that	 fuse	
with	lysosomes	and	become	digested	by	lysosomal	enzymes44.	Autophagy	genes	




and	 other	 wasting	 conditions,	 and	 trans-	 genic	 expression	 of	 PGC-1a	 rescues	
muscle	loss	in	part	by	inhibiting	Foxo3	and	through	the	production	of	metabolic	
products.	PGC-1a	is	highly	induced	during	exercise,	and	one	of	the	primary	roles	
of	 this	 factor	 is	 to	 regulate	 mitochondrial	 biogenesis	 and	 oxidative	
phosphorylation	 in	 myofibers,	 characteristic	 of	 type	 I,	 fatigue-resistant,	
muscles46.	Interestingly,	in	cancer	cachexia,	muscle	atrophy	is	selective	to	type	II	
fast	twitch	myofibers,	while	type	I	oxidative	fibers	are	relatively	spared	of	similar	
catabolic	effects47.	 Therefore,	 it	 is	possible	 that	 this	 sparing	effect	 results	 from	
PGC-1a	 inhibition	 of	 Foxo3	 activity	 in	 type	 I	myofibers.	 Attempts	 to	 screen	 for	
PGC-1a	activators	represents	a	promising	therapeutic	avenue	to	prevent	muscle	
atrophy	in	cancer	or	other	catabolic	conditions.		
Since	 even	 in	 cachectic	 patients	 there	 is	 the	 experience	 of	 both	 a	
decrease	 in	 lean	body	mass	 (atrophy)	 and	muscle	weakness	 (loss	of	 strength	 /	
functional	 parameters),	 we	 decided	 to	 investigate	 whether	 also	 in	 cachectic	






Skeletal	 muscle	 is	 a	 major	 site	 of	 metabolic	 activity	 and	 is	 the	 most	
abundant	tissue	in	the	human	body.	During	development,	the	growth	of	skeletal	
muscle	mass	depends	on	protein	and	cellular	 turnover48.	 In	adulthood,	skeletal	
muscle	adapts	 its	 size	and	 function	 to	different	physiological	 requirements	and	
pathophysiological	conditions,	primarily	by	affecting	pathways	regulating	protein	
turnover.	 In	particular,	 the	size	of	post-mitotic	cells	 is	determined	by	a	balance	
between	new	protein	 accumulation	 and	 the	degradation	of	 existing	proteins49.	
Few	pathways	have	been	 identified	 that	 regulate	muscle	 growth	 in	 adulthood,	
and,	 among	 these,	 myostatin,	 a	 transforming	 growth	 factor	 (TGF)-β	 family	
member	 has	 a	 key	 role	 as	 a	 negative	 regulator50,51.	 Myostatin	 signals	 via	 the	
activin	type	II	receptors	(ActRIIA	and	ActRIIB)	and	activin	type	I	receptors	(ALK4	
and	 ALK5)	 to	 phosphorylate	 responsive	 Smad	 proteins	 (Smad2	 and	 Smad3,	
Smad2/3),	which	 enables	 the	 Smad	proteins	 to	 form	 a	 transcriptional	 complex	
with	Smad4	to	transcribe	target	genes.	Several	genetic	and	biochemical	studies	
have	 shown	 that	 inhibition	 of	 the	 myostatin-ActRIIB-ALK4/	 ALK5-Smad2/3	









protein	 family	 and	 control	 cell	 growth	 and	 differentiation55.	 BMP	 signaling	 is	
mostly	 known	 for	 its	 roles	 in	 embryonic	 development	 and	 in	 bone/cartilage	
formation54.	 In	 adult	 skeletal	 muscle,	 activation	 of	 BMPs	 has	 been	 associated	




the	 homeostasis	 of	 adult	 tissues	 and	 its	 relationship	 with	 myostatin	 signaling	
remain	largely	unknown.		
The	study	published	by	Sartori	et	al.	in	2013	provides	several	new	insights	
into	 signaling	 by	 TGF-β	 pathways	 and	 their	 contribution	 to	 the	 regulation	 of	
muscle	 mass	 in	 adulthood.	 BMP	 signaling	 resulted	 as	 the	 dominant	 pathway	
controlling	 muscle	 mass,	 even	 more	 so	 than	 myostatin.	 In	 particular,	 the	
hypertrophic	 phenotype	 caused	 by	 myostatin	 inhibition	 in	 fact	 results	 from	
unrestrained	 BMP	 signaling.	 This	 fits	 with	 a	model	 in	 which	 a	 decrease	 in	 the	
levels	 of	 phosphorylated	 Smad2/3	 leads	 to	 the	 release	 of	 Smad4,	 which	 is	
recruited	 into	 BMP	 signaling	 to	 promote	 hypertrophy	 and	 counteract	 atrophy.	
Conversely,	 when	 the	 BMP	 pathway	 is	 blocked	 or	 myostatin	 expression	 is	
increased,	more	Smad4	 is	available	 for	phosphorylated	Smad2/3,	 leading	 to	an	
atrophy	 response.	 Therefore,	 under	 normal	 circumstances,	 a	 balance	 between	
these	 competing	 pathways	 is	 required	 to	maintain	muscle	mass.	 The	 dramatic	
loss	 of	 muscle	mass	 after	 denervation	 in	 Smad4	 knockout	mice	 and	 following	
overexpression	of	noggin,	that	inhibits	BMP	pathway,	strongly	suggests	that	BMP	
signaling	 is	 also	 required	 to	 prevent	 excessive	 muscle	 loss	 under	 pathological	
conditions.	Similar	conclusions	have	been	reached	by	an	 independent	study	on	





MUSA1	 undergoes	 autoubiquitination.	 Thus,	 it	 is	 reasonable	 to	 suggest	 that	
increased	 ligase	 activity	 of	 MUSA1	 during	 denervation	 would	 amplify	 its	
autoubiquitination	 activity,	 resulting	 in	 increased	 proteasome-dependent	
degradation.	 Therefore,	 transcriptional	 upregulation	 is	 particularly	 important,	
mostly	to	replenish	the	loss	of	MUSA1	protein	that	occurs	in	denervated	muscles	
as	a	consequence	of	increased	MUSA1	activity.	BMP	signaling	is	indispensable	for	















1.4	 ROLE	 OF	 DENERVATION	 IN	
MUSCULAR	ATROPHY	
 
Many	 of	 publications	 on	 relation	 between	 denervation	 and	 muscular	
atrophy	 are	 about	 denervation	 in	 aging.	 Aging	 is	 characterized	 by	 a	 gradual	
decline	that	 impairs	cell	homeostasis	and	functional	reserves.	Histologic	studies	
of	 skeletal	 muscle	 have	 shown	 that	 denervation	 is	 among	 the	 numerous	
mechanisms	that	contribute	 to	 tissue	atrophy	and	degeneration	 in	aging58.	The	
term	‘‘disseminated	neurogenic	atrophy’’	was	coined	to	describe	the	progressive	
accumulation	 and	 clustering	 of	 small	 angulated	 fibers	 with	 aging;	 this	






suggest	 that	 some	 reinnervation	 events	 follow	 muscle	 fiber	 denervation60.	
Further	 evidence	 supporting	 the	 occurrence	 of	 rounds	 of	 denervation	 and	
reinnervation	 includes	 the	 increased	 clustering	 of	myofiber	 types	 in	 the	motor	
units	 of	 rodents	 and	 other	 mammals	 as	 they	 age61.	 In	 adult	 humans,	 the	
incomplete	 reinnervation	of	 fibers	by	 surviving	motor	neurons,	may	 contribute	
to	 loss	 of	 muscle	 strength	 and	 mass	 as	 people	 grow	 older62.	 These	
rearrangement	processes	are	generally	accompanied	by	a	progressive	increase	in	
the	 proportion	 of	 slow	muscle	 fibers,	 although	 there	 is	 some	 evidence	 to	 the	
contrary63.	 Some	 of	 the	 discrepancies	 have	 been	 dispelled	 by	 comparisons	 of	
muscle	from	normally	active	and	immobile	older	patients	that	show	that	muscle	
wasting	 in	 ‘‘normally	 active’’	 seniors	 is	 accompanied	 by	 a	 shift	 toward	 a	 slow-
twitch	 phenotype,	 whereas	 inactive	 seniors	 demonstrates	 a	 shift	 toward	 fast-
twitch	 isoform	 expression.	 This	 latter	 case	 is	 common	 in	 ‘‘unloaded’’	 muscle	
undergoing	 atrophy,	 for	 example,	 during	 limb	 suspension,	 immobilization,	
paralysis,	 and	 spaceflight64.	 To	 complicate	 the	 situation	 further,	 conflicting	
results	 regarding	 fast	 to	 slow	 myosin	 transition	 arise	 in	 endurance	 training	
studies	 using	 animal	 models	 and	 in	 clinical	 trials	 of	 humans	 involving	 either	
voluntary	 exercise	 or	 electrical	 stimulation	 both	 directly	 to	 denervated	muscle	
and	 indirectly	 to	muscle	 through	nerve	stimulation65,66.	 Furthermore,	 increased	
exercise	that	is	sustained	for	decades	protects	against	age-related	loss	of	motor	




related	 shifts	 are	 under	 neural	 control	 or	 the	 result	 of	 the	 direct	 influence	 of	
use/disuse	on	myogenic	processes	 remains	 to	be	clarified.	Histologic	 studies	of	



























patient	with	 BMI	 <20	 or	 with	 a	 diagnosis	 of	 sarcopenia.	 For	 each	 patient,	 the	
nutritional	 status	 is	 detected	 by	 calculating	 BMI,	 weight	 loss,	 food	 intake	
assessment,	 the	 dosage	 of	 inflammatory	 markers	 and	 biohumoral	 markers	 of	




The	 project	 includes	 the	 collection	 of	 a	 blood	 sample	 and	 one	 muscle	
biopsies	 (rectus	 abdominis).	 Blood	 and	 muscle	 tissue	 sampling	 is	 taken	
simultaneously	at	surgery.	
All	patients	will	 then	be	 inserted	 in	a	clinical	and	 instrumental	follow-up	








-	 Patients	 with	 esophageal,	 colorectal	 or	 pancreatic	 cancer	 at	 any	 stage	
according	to	TNM	classification	7th		




























for	 biochemical	 and	 molecular	 and	 gene	 expression	 analysis,	 the	 other	 was	







Total	 RNA	 was	 prepared	 from	 skeletal	 muscles	 using	 Promega	 SV	 Total	 RNA	









	 A	 relative	 quantification	method	was	 used	 to	 evaluate	 the	 differences	 in	
gene	expression,	as	described	by	Pfaffl	(Pfaffl,	2001).		


























Then	 the	 solution	 was	 incubated	 at	 1200	 rpm	 for	 10	 min	 at	 +70°C.	 After	
centrifugation	 at	 13,000	 rpm	 for	 10	 min	 at	 +4°C,	 we	 measured	 the	 protein	





Techologies)	 and	 50mM	 DTT.	 The	 samples	 were	 denaturated	 at	 95°C	 for	 5	
minutes	 at	 1250	 rpm	 and	 loaded	 on	 SDS	 4-12	 %	 precast	 polyacrylamide	 gels	






400mA	for	1	hour	and	30	minutes	at	+4°C.	The following primary antibodies were 
used: 
	 Anti	 phospho-Smad1	 (Ser463/465)/	 Smad5	 (Ser463/465)/	 Smad9	
(Ser465/467)	 (D5B10)	 Rabbit	 mAb	#13820	 by	 Cell	 Signaling	 Technology,	 anti	
phospho-Smad3	(Ser423	+	Ser425)	Rabbit	mAb	[EP823Y]	(ab52903)	by	Epitomics	
and	anti	GAPDH	mouse	monoclonal	(ab8245)	by	Abcam.	
	 Immunoreaction	 was	 revealed	 by	 enhanced	 chemiluminescent	 method	







Serial	 cross-sections	 (8	um	 thickness)	 from	 frozen	muscle	biopsies	were	
mounted	 on	 polysine	 glass	 slides,	 air-dried	 and	 used	 for	 further	 analyses.	 For	
morphometric	analysis,	the	mean	muscle	fiber	diameter	was	evaluated	 in	H&E-
stained	cross-sections	in	accordance	to	Refs.8	and	9	using	Scion	Image	software	
for	 Windows,	 version	 Beta	 4.	 0.2	 (2000,	 Scion	 Corporation,	 Inc.;	





nuclei	 were	 counted	 and	 categorized	 as	 located	 inside	 or	 outside	 the	 muscle	
fiber,	within	the	extracellular	matrix.		
To	 give	 an	 expression	 of	 the	 number	 of	 very	 small	 fibers,	 the	 atrophy	
factor	was	calculated	in	muscle	biopsies	as	described	by	Dubowitz	(1985).	To	put	
the	 results	 in	 a	 proportional	 basis,	 the	 total	 number	 of	 fibers	 having	 diameter	
between	40	and	30	um,	30	and	20	um,	20	and	10	um,	and	less	than	10	um	was	
counted	and	multiplied	by	one,	two,	three,	and	four,	respectively.	The	products	










X	 5	minutes	 in	 PBS,	 and	 then	 incubated	 for	 1	 hour	 at	 room	 temperature	with	
Cy3-labeled	conjugates	directed	against	rabbit	IgG	(SigmaAldrich)	1	:	200	diluted	
in	 10%	 goat	 serum/	 PBS.	 Negative	 controls	 were	 performed	 by	 omitting	 the	
primary	antibodies	on	samples. Coverslips	were	mounted	onto	glass	slides	using	
ProLong	 Gold	 anti-fade	 reagent	 with	 DAPI	 to	 counterstain	 nuclei	 (Life	
Technologies)	 and	 observed	 under	 the	 fluorescent	 microscope.	 Images	 were	
acquired	as	described	above,	and	the	number	of	N-CAM-positive	myofibers	were	









The	 statistical	 significance	 of	 data	 collected	 was	 determined	 using	 a	
Student’s	t	test	(Microcal		Origin_	6.0;	Microcal	Software,	Inc.)	and	a	chi-squared	
test	(Microsoft_	Office	Excel_	2007;	Microsoft	Corporation).	Statistical	analysis	of	
morphometric	 datasets	 was	 performed	 with	 GraphPad	 Prism	 v5.0	 software;	
statistical	 significance	 of	 average	 numbers	 was	 determined	 using	 Wilcoxon	
matched	pairs	test.	Values	of	P	<	0.05	were	considered	significant.		
Statistical	 analysis	 of	 densitometric	 and	 gene	 expression	 datasets	 was	
performed	with	GraphPad	Prism	v6.0	software.	Data	were	analyzed	by	two-tailed	













From	 December	 2014	 to	 2016	 we	 collected	 rectus	 abdominis	 muscle	
biopsies	from	93	patients	suffering	from	gastro-enteric	neoplasms,	treated	at	3rd	
Surgical	 clinic	 of	 University	 of	 Padua.	 They	 underwent	 median	 laparotomy	
surgery.	 In	 the	same	period	we	collected	biopsies	 from	11	control	 subjects	who	
underwent	laparotomy	for	non-neoplastic	and	non-inflammatory	diseases.	




























were	 cachectic,	 versus	 58,8%	 of	 pancreatic	 cancer	 patients	 and	 60%	 of	 other	
cancer	type	patients	(p	n.s.).	
At	 the	beginning	of	 the	study	we	performed	comprehensive	preliminary	
analysis	 of	 all	 patients,	 however,	 we	 immediately	 found,	 among	 patients	 with	
gastric	and	esophageal	cancer,	a	high	variability	and	heterogeneity	in	the	results	
obtained	possibly	due	to	the	presence	of	severe	dysphagia	and	the	presence	of	
nutritional	 support,	 as	 like	 as	naso-gastric	 tube.	We	have	 therefore	decided	 to	
consider	the	data	of	these	patients	as	a	possible	source	of	BIAS	for	the	study	and	
therefore	 to	 exclude	 them	 from	 the	 study	 including	 in	 the	 final	 data	 analysis,	
only	 colorectal	 and	 pancreatic	 cancer	 patients,	 (59	 patients	 overall)	 two	
malignancies	 in	 which	 cachexia	 reaches	 80%	 incidence.	 The	 analysis	 of	 all	







Since	 inhibition	 or	 reduction	 of	 BMP	 signaling	 in	 mice	 induces	 an	
exacerbated	muscle	loss	that	mimics	cachexia,	in	the	first	phase	of	the	study	we	
monitored	the	status	of	activation	of	BMP	pathway	in	muscles	of	cancer	patients	
by	 examining	 the	 phosphorylation	 levels	 of	 Smad1/5/8,	 the	 downstream	
effectors	 of	 BMP.	 	 Very	 preliminary	 results	 indicate	 that	 the	 BMP	 pathway	 is	
downregulated	 in	muscles	of	 cachectic	patients	 compared	 to	age-matched	non	
cachectic	ones	in	both	colorectal	and	pancreatic	patients.	
The	suppression	of	BMP	pathway	 is	 in	 line	with	the	hypothesis	 that	 this	


















































We	 need	 to	 stress	 the	 fact	 that	 these	 are	 very	 preliminary	 results,	 we	
need	 to	 increase	 both	 the	 number	 of	 cancer	 patients	 and	 of	 control	 patients	







To	 explain	 why	 Smad1/5/8	 are	 inhibited	 we	 monitored	 the	 expression	
levels	 of	 Noggin,	 a	 well-known	 inhibitor	 of	 BMP	 pathway.	 Noggin	 is	 an	
extracellular	antagonist	of	BMP	ligands	preventing	their	binding	to	the	receptors.	
The	expression	of	Noggin	was	highly	 increased	 in	muscles	of	cachectic	patients	

































Since	 we	 have	 shown	 that	 the	 BMP	 pathway	 negatively	 regulates	 the	
expression	of	a	novel	ubiquitin	 ligase	(MUSA1),	we	tested	whether	MUSA1	was	
also	 induced	 in	 cancer	 cachexia	 and	 we	 compared	 its	 expression	 with	 the	
expression	 of	 the	 well-known	 atrophy-related	 muscle-specific	 ubiquitin	 ligases	
atrogin1	and	MuRF1.	While	we	could	not	detect	any	significant	difference	in	the	
expression	of	atrogin1,	both	MuRF1	and	MUSA1	were	significantly	up-regulated	











































These	 results	 have	 statistically	 significance	 especially	 in	 the	 case	 of	
MUSA1,	whose	up-regulation	is	in	line	with	the	observation	that	BMP	pathway	is	
inhibited	 during	 cancer	 progression.	 Moreover,	 the	 analysis	 of	 correlation	
between	 the	 percentage	 of	 body	 weight	 loss	 and	 the	 atrogenes	 expression	
demonstrates	a	significant	positive	correlation	between	the	expression	levels	of	
MUSA-1	and	the	percentage	of	body	weight	loss.	On	the	contrary,	no	significant	


































































Histological	 analyses	 of	 muscle	 biopsies	 from	 cancer	 patients	 showed	
numerous	severely	atrophic,	flat	shaped	and	angulated	fibers,	as	typical	signs	of	
denervation.	These	morphological	aspects	were	only	seldom	detected	in	muscle	

































smaller	 values	 in	 muscle	 biopsies	 from	 cancer	 patients	 in	 comparison	 to	 age	
matched	controls,	as	indicated	by	the	myofiber	diameter	distribution	reported	in	
the	 graph	 here	 below.	 This	 shift	 is	 particularly	 evident	 in	 cachectic	 patients	 as	











































revealed	 numerous	 fiber	 type	 grouping	 identified	 on	 the	 basis	 that	 at	 least	 1	
muscle	 fiber	 is	 completely	 surrounded	by	 fibers	of	 the	 same	phenotype.	 Fiber-
type	 groupings	 are	 typical	 hallmark	 of	 denervation/reinnervation	 events	 of	
surviving	muscle	fibers	by	the	neighbours	motor	neurons.		
The	 ATPase	 histochemistry	 here	 below	 show	 the	 slow	 type	 fibers	 dark	


























sarcoplasmImmunofluorescence	 analyses	 revealed	 the	 presence	 of	 several	 N-
CAM	positive	fibers,	particularly	in	the	muscle	of	cancer	patients.	
The	 percentage	 of	 N-CAM	 expressing	 myofibers	 was	 significantly	







































We	also	checked	by	real	 time	PCR	the	expression	 in	 the	muscles	of	 two	





























myofiber	 atrophy	 in	 cancer	 cachexia.	 This	 is	 completely	 new	 pathogenetic	
mechanism	 underlying	 muscle	 atrophy	 during	 cancer	 progression	 that	 we	 are	
analyzing	 in	more	detail.	 To	do	 that,	we	are	 increasing	 the	number	of	patients	
analyzed	 for	 markers	 of	 denervation	 (MuSK	 and	 AchRg)	 and	 we	 are	 analyzing	
other	 transcriptional	 markers	 of	 denervation	 (myogenin,	 NCAM,	 Runx1)	 and	














Cancer	 cachexia	 affects	 80%	 of	 cancer	 patients.	 It	 is	 an	 independent	
prognostic	 factor	 and	 it’s	 directly	 responsible	 for	 death	 in	 20-30%	 of	 cancer	








autophagy	 lysosome	 systems.	 Enhancement	 of	 protein	 breakdown	 requires	 a	
transcriptional	 dependent	 program	 that	 induces	 the	 expression	 of	 a	 subset	 of	












Sartori	et	al.	has	cleared	 that	 the	BMP	pathway	has	a	 fundamental	 role	
limiting	 protein	 degradation	 in	 mice	 models	 of	 muscle	 atrophy	 through	 the	
inhibition	of	the	synthesis	of	a	newly	detected	E3	ubiquitin	ligase,	MUSA-1,	and	
that	 its	 inhibition	 is	 a	 necessary	 condition	 for	 the	 onset	 of	 muscle	 atrophy,	
regardless	 of	 the	 state	 of	 activation	 of	 myostatin	 pathway.	 Inhibition	 of	 BMP	
pathway	 induces	 an	 excessive	 muscle	 loss	 and	 tremendous	 weakness	 during	
catabolic	 conditions	 such	 as	 absence	 of	 nutrients	 or	 denervation,	well	 copying	
the	cachexia	phenotype.	
The	 preliminary	 results	 of	 our	 study	 confirm	 that	 BMP	 pathway	 is	
downregulated	 in	 muscles	 of	 cachectic	 cancer	 patients	 compared	 to	 non-
cachectic	ones.	On	 the	contrary	we	didn’t	detect	any	difference	 in	 the	state	of	
activation	 of	 the	 myostatin/TGFb	 pathway.	 These	 observations	 support	 the	
hypothesis	that	a	decrease	of	BMP	signal	is	a	permissive	condition	for	the	onset	
of	muscle	 loss	 and	of	 cachexia	 syndrome	 in	 cancer	 patients.	Moreover,	 the	 E3	
ubiquitin	 ligases	MuRF1	and	MUSA1	are	significantly	upregulated	 in	muscles	of	
human	cachectic	patients	 compared	 to	age-matched	non	cachectic	and	control	




potentially	 explaining	why	 BMP	pathway	 is	 blocked	 during	 cancer	 progression.	
Interestingly,	 there	 is	 positive	 correlation	 between	 the	 muscle	 expression	 of	
MUSA1	 (but	not	Atrogin1	and	MuRF1)	and	Noggin	and	the	percentage	of	body	
weight	loss	in	the	patients.	
Previous	 studies	 (Sartori	et	al)	demonstrated	 that	 the	overexpression	of	




Numerous	 myofibers	 with	 typical	 features	 of	 denervation	 were	
predominantly	 detected	 in	 skeletal	 muscle	 biopsies	 from	 (either	 cachectic	 or	
non-cachectic)	toghether	with	a	higher	prevalence	of	N-CAM	positive	myofibers	
(i.e.	 denervated	 myofibers)	 and	 several	 fiber	 type	 grouping	 (i.e.	 features	 of	
denervation/reinnervation	events).		
Moreover,	 cancer	 patients,	 in	 particular	 cachetic	 ones,	 showed	
the		smallest	myofiber	diameter	and	the	highest	atrophy	index	when	compared	
to	 non-cachetic	 and	 control	 subjects,	 indicating	 that	 muscle	 atrophy	 was	 a	
predominant	feature	in	cachetic	patients.	
These	 results	 suggest	 that	 denervation	 may	 contribute	 to	 myofiber	
atrophy	 in	 cancer	 cachexia.	 To	 better	 clarify	 this	 point	 we	 also	 checked	 the	
expression	in	the	muscles	of	two	other	marker	of	denervation	(MuSK	and	AchRg)	
and,	 even	 if	 the	 result	 presented	 is	 still	 not	 statistically	 significant,	 there	 is	 an	
interesting	 trend	 toward	 higher	 levels	 of	 expression	 of	 both	 markers	 in	 the	
muscles	of	cancer	patients	compared	to	control	subjects	suggesting	an	ongoing	
degeneration	of	 the	neuromuscular	 junction	 in	 the	muscles	of	 cancer	patients.	
This	 result	 is	 the	 more	 interesting	 because	 so	 far	 no	 one	 has	 identified	
denervation	as	a	pathogenetic	mechanism	underlying	muscle	atrophy	 in	cancer	
patients.	 Serological	 testing	 for	 NMJ	 degeneration/denervation	 biomarkers	 in	
the	different	groups	of	patients	(control	and	cancer,	cachectic	and	non-cachectic,	




with	 the	 clinical	 characteristics	 of	 the	 study	 population	 trying	 to	 figure	 out	 if	
there	 is	 a	 prognostic	 value	 associated	 with	 the	 activation	 of	 the	 different	
pathways	and	identify	if,	in	precachectic	cancer	patients,	the	activation	profile	of	
the	BMP	pathway	and	the	ubiquitin	ligase	is	different,	to	understand	what	is	the	






The	 ultimate	 goal	 of	 this	 research	 project	 is	 the	 development	 of	 a	
therapeutic	 strategy	 aimed	 to	 counteract	 the	 occurrence	 and	 to	 limit	 the	
progression	of	muscle	atrophy	in	cancer	patients.	Preliminary	results	obtained	in	
preclinical	 studies	 (data	 not	 shown)	 demonstrated	 that	 the	 reactivation	 of	 the	
BMP	pathway	by	 the	overexpression	of	a	constitutive	active	 form	of	 the	 type	 I	
BMP	receptor	is	able	to	prevent	atrophy	in	tumor	bearing	mice.	However,	these	
results	do	not	discriminate	which	BMP	ligand	is	involved	in	this	beneficial	effects	
on	 muscle	 mass.	 The	 identification	 of	 the	 critical	 BMP	 or	 of	 the	 critical	
combination	 of	 BMPs	 would	 have	 important	 consequences	 in	 terms	 of	
therapeutic	 approach	 for	 cancer	 patients.	 For	 this	 reason	 we	 are	 screening	
different	 BMP	 ligand	 in	 order	 to	 determine	which	one	 is	 important	 to	 prevent	
muscle	 loss.	The	critical	one	will	be	systemically	administered	 in	 tumor	bearing	
animals	 and	 the	 effects	 on	 animal	 survival	 and	 cachexia	 syndrome	 will	 be	
monitored.	Preliminary	results	point	to	BMP7	as	a	very	interesting	candidate.	
Moreover,	we	are	developing,	in	collaboration	with	a	drug	designer	team,	
a	 peptide	 able	 to	 competitively	 inhibit	 the	 binding	 of	 Noggin	 with	 BMP7.	
Synthesizing	a	peptide	of	this	type,	however,	 is	technically	complex,	because	of	
chemical	instability	of	the	peptides	obtained,	and	it	is	economically	onerous.	For	














	 The	 results	 obtained	 in	 this	 study	 will	 clarify	 the	 role	 played	 by	
Noggin/BMP/MUSA1	 axis	 in	 cancer-induced	 muscle	 loss	 and	 its	 potential	
implication	 as	 a	 therapeutic	 approach	 to	 counteract	 cachexia	 syndrome	 and	
improve	 survival.	 Moreover	 we	 have	 identified	 denervation	 as	 a	 new	
pathogenetic	 trait	underlying	muscle	atrophy	 in	 cancer	patients.	 The	 impact	of	
preventing	 cachexia	 is	 an	 important	 aspect	 for	 patient	 treatment	 and	 survival.	
Our	data	will	identify	BMPs	as	biomarkers	suitable	to	identify	patients	at	risk	to	
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